| Latrobe Magnesium Limited (LMG) ORDINARY FULLY PAID |
Materials |
$31 |
Latrobe Magnesium Achieves Continuous MgO Production
|
27 Feb 2026 9:34AM |
$0.020 |
$0.009 |
fallen by
55%
|
|
LMG - Price-sensitive ASX Announcement
Full Release
Key Points
- Development of a magnesium metal Demonstration Plant in Victoria's Latrobe Valley.
- Utilizing a patented extraction process on industrial ash waste.
- First half of the plant achieved sustained magnesium oxide production.
- Full Demonstration Plant commissioning expected in second half of 2026.
- Planned Commercial Plant with 10,000 tonnes per annum capacity.
- International 'Mega' Plant in Sarawak, Malaysia for 100,000 tonnes annually.
- Commitment to recycling, reducing landfill, and low carbon emissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$134 |
Appendix 4G and Corporate Governance Statement
|
27 Feb 2026 9:34AM |
$0.875 |
$0.770 |
fallen by
12%
|
|
| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$29 |
1H26 Results Release
|
27 Feb 2026 9:34AM |
$0.180 |
$0.120 |
fallen by
33.33%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY26 revenue of A$29.0m, down A$3.0m
- Underlying EBITDA loss of A$5.9m
- Record European contract signings of A$6.9m
- Strong Latin American contract momentum
- First corporate-funded contract in the US worth A$2.3m
- Potential A$30m in tender projects
- A$9.3m in new work contracted in H2 FY26
- Expecting a stronger second half of FY26
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medallion Metals Limited (MM8) ORDINARY FULLY PAID |
Materials |
$418 |
Acquisition Completion
|
27 Feb 2026 9:34AM |
$0.425 |
$0.520 |
risen by
22.35%
|
|
MM8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of the acquisition of Forrestania Nickel Operation from IGO Limited.
- Forrestania Nickel Operation to be renamed Forrestania Gold Project.
- Medallion assumes full statutory and operational responsibility for the asset.
- Acquisition provides control over critical processing infrastructure.
- Transaction supports Medallion's long-term gold processing and development strategies.
- Key approvals, funding, and transaction milestones achieved.
- Handover set for 27 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$413 |
Trading Halt
|
27 Feb 2026 9:33AM |
$0.160 |
$0.089 |
fallen by
44.38%
|
|
SGQ - Price-sensitive ASX Announcement
Full Release
Key Points
- St George Mining Limited requested a trading halt on its securities.
- Trading halt is pending an announcement regarding a substantial increase to the Company's Mineral Resource Estimate at the Araxa Project.
- The trading halt will remain until the earlier of the announcement release or the commencement of normal trading on Tuesday, 3 March 2026.
- St George Mining is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$164 |
ACW successfully completes $16.8m Placement and SPP
|
27 Feb 2026 9:33AM |
$0.042 |
$0.044 |
risen by
4.76%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical successfully completed a $16.8 million capital raising.
- $4.8 million was raised via a share purchase plan (SPP).
- The capital raising included a $12.0 million placement.
- The SPP was offered at $0.042 per share.
- 114 million new shares will be issued to SPP participants.
- CEO Dr. Steven Gourlay and non-executive directors committed to purchasing additional shares.
- The funds will support the XanaMIA phase 2b/3 Alzheimer’s trial and other initiatives.
- The company expects to have a cash balance of $29.5 million by December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$29 |
1H26 Appendix 4D and Half Year Report
|
27 Feb 2026 9:33AM |
$0.180 |
$0.120 |
fallen by
33.33%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- Rubicon Water Limited reported a net loss after tax of $6,390,000 for the six months ended 31 December 2025.
- Revenue for the first half of 2025 was $29,022,000, down from $32,018,000 in the same period of 2024.
- The most significant revenue decline occurred in the ANZ segment, primarily due to decreased hardware and spare parts sales.
- Underlying EBITDA was a loss of $5,854,000, compared to a loss of $1,694,000 in the previous year.
- Rubicon Water Limited did not declare or pay any dividends during the reporting period.
- Net tangible assets per ordinary security decreased from $0.27 in 2024 to $0.21 in 2025.
- Exchange rate fluctuations contributed to a $2.1 million negative impact year-on-year due to a stronger Australian dollar.
- The Asia segment is expected to recover in the second half of the year with increased project activity.
- The company has joint ventures, including Medha Rubicon Water Technologies Pvt Ltd, in which it holds a 50% ownership interest.
- No significant events occurred after the reporting date that would impact the financial statements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$45 |
Application for quotation of securities - NUZ
|
27 Feb 2026 9:32AM |
$0.100 |
$0.058 |
fallen by
42%
|
|
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$43 |
Annual Report to shareholders
|
27 Feb 2026 9:32AM |
$0.036 |
$0.037 |
risen by
2.78%
|
|
| Alpha HPA Limited (A4N) ORDINARY FULLY PAID |
Materials |
$770 |
Application for quotation of securities - A4N
|
27 Feb 2026 9:32AM |
$0.650 |
$0.530 |
fallen by
18.46%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$4 |
Appendix 4D and Half Year Financial Report
|
27 Feb 2026 9:32AM |
$0.081 |
$0.037 |
fallen by
54.32%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss after income tax for the half-year: $3,565,836
- Total assets as of 31 December 2025: $8,088,461
- Net assets as of 31 December 2025: $5,706,180
- No dividends paid or declared during the period
- Convertible notes issued for additional funding
- Significant expenditure on research and development
- PhotosoftTM technology focus and potential Orphan Drug Designation
- R&D tax incentive loan facility secured
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$361 |
FY25 Appendix 4E Preliminary Final Report
|
27 Feb 2026 9:31AM |
$1.235 |
$1.225 |
fallen by
0.81%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Profit After Tax increased by 20% to PGK 120.7 million.
- Revenue from ordinary activities rose by 13% to PGK 545.5 million.
- Net interest income increased by 20%.
- Foreign exchange income grew by 17%.
- Unfranked dividends declared at AUD 6.5 cents per share.
- Operating expenses increased by 4%.
- Cost-to-income ratio improved to 54.7%.
- Loans and advances to customers increased by 13%.
- Capital adequacy ratios remained strong at 17.1%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 |
Health Care |
$1,272 |
2025 Financial Results and Corporate Update
|
27 Feb 2026 9:31AM |
$8.870 |
$13.050 |
risen by
47.13%
|
|
AVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Initiated global pivotal PARADIGM Trial.
- Favorable 30-day and 1-year outcomes for DurAVR® THV.
- First successful double DurAVR® implant.
- Strengthened operational infrastructure and manufacturing capabilities.
- ISO 13485 certification for DurAVR® THV production.
- Net operating cash outflows of US$77.8 million in 2025.
- R&D expenses totaled US$69.1 million.
- Secured US$320 million in capital raises, including Medtronic investment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Platinum International Fund (Quoted Managed Hedge Fund) (PIXX) |
Financials |
$63 |
2026 Interim Financial Report
|
27 Feb 2026 9:31AM |
$5.050 |
$4.970 |
fallen by
1.58%
|
|
| Associate Global Partners Limited (APL) ORDINARY FULLY PAID |
Financials |
$16 |
Investor Presentation February 2026
|
27 Feb 2026 9:30AM |
$0.180 |
$0.265 |
risen by
47.22%
|
|
APL - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive net inflows recorded in H1 FY2026.
- FUM reached $1.42 billion by December 2025.
- WCM product suite contributed significantly to FUM growth.
- Partnership with Switzer Financial Group enhances direct business capabilities.
- Strategic focus on expanding manager partnerships and launching new products.
- Achieved operating profitability in H1 FY26.
- Revenue increased by 10.2% in H1 FY26.
- Net loss reduced by 92.3% in H1 FY26.
- Five consecutive quarters of positive operating cash flow achieved.
- Ongoing initiatives to diversify investor base and drive sustainable growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bass Oil Limited (BAS) ORDINARY FULLY PAID |
Energy |
$20 |
Operations Update - January 2026
|
27 Feb 2026 9:30AM |
$0.050 |
$0.054 |
risen by
8%
|
|
BAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Total sales revenue for January was A$471,374 net to Bass.
- Daily oil production for the group averaged 237 bopd for the month.
- Total Cooper Basin monthly production was 2,746 barrels.
- Total Indonesian oil production was 4,596 barrels net to Bass.
- Vanessa acquisition was approved by the regulator.
- Bass secured $3.5 million grant funding for Kiwi gas field development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$63 |
Strong Revenue Growth,Improved Profitability & Positive NPAT
|
27 Feb 2026 9:30AM |
$0.605 |
$0.595 |
fallen by
1.65%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Raiz Invest Limited reported a strong 23.9% revenue growth for the half-year ended 31 December 2025.
- Funds Under Management (FUM) increased by 28.5% to $2.1 billion.
- Raiz achieved a Net Profit After Tax (NPAT) of $3.52 million, transitioning from a previous loss.
- The company's operating cash flows increased by 51.4% to $2.36 million.
- Underlying EBITDA increased by 270% to $2.6 million.
- Raiz's active customer base grew by 5.7% to 336,048.
- Raiz introduced new product offerings like the low-cost Raiz Lite Plan and expanded its product roadmap for 2026.
- The company maintained strategic partnerships to enhance product offerings and entered new partnerships to promote financial education.
- Raiz's Plus Plan portfolios increased by 33.6%, reflecting strong market acceptance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Platinum Asia Fund (Quoted Managed Hedge Fund) (PAXX) |
Financials |
$279 |
2026 Interim Financial Report
|
27 Feb 2026 9:29AM |
$6.460 |
$5.820 |
fallen by
9.91%
|
|
| GLG Corp Limited (GLE) ORDINARY FULLY PAID |
Consumer Discretionary |
$10 |
Half Year Financial Report and Appendix 4D
|
27 Feb 2026 9:29AM |
$0.115 |
$0.140 |
risen by
21.74%
|
|
GLE - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 18.7% to US$54.1m.
- Gross profit margin improved from 17.7% to 18.9%.
- Net loss after tax was US$0.5m compared to a profit of US$0.4m in the previous period.
- No interim dividend recommended for the period ended 31 December 2025.
- Finance costs increased by 10.1% due to higher working capital requirements.
- Cash and cash equivalents decreased slightly by US$0.2m.
- Trade and other receivables decreased by 9.5%.
- Inventory decreased by 14.8% due to lower customer orders.
- Administrative expenses fell by 8.4% through cost control measures.
- Management focuses on working capital optimization and liquidity preservation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| One Click Group Limited (1CG) ORDINARY FULLY PAID |
Industrials |
$12 |
Appendix 4E and Annual Report to Shareholders
|
27 Feb 2026 9:27AM |
$0.009 |
$0.009 |
fallen by
0%
|
|
1CG - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidated revenue increased from $4.88 million in 2024 to $6.12 million in 2025.
- The company reported a net loss after tax of $716,460 for 2025 compared to a loss of $1.98 million in 2024.
- Total assets for 2025 stood at $4.67 million, slightly higher than $4.53 million in 2024.
- The company's equity increased to $3.64 million in 2025 from $2.94 million in 2024.
- Significant shareholdings and options details include various family accounts and trusts holding substantial percentages.
- Directors and key management personnel hold significant options and performance rights.
- The company engaged in share-based payments and financial transactions to manage equity and reserves.
- Employee expenses and other operational costs were reported with specific focus on superannuation and other benefits.
- The company did not engage in any on-market buy-back activities during the year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$37 |
Update - Notification of buy-back - MEC
|
27 Feb 2026 9:27AM |
$1.195 |
$1.240 |
risen by
3.77%
|
|
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$45 |
Section 708A Cleansing Statement
|
27 Feb 2026 9:27AM |
$0.100 |
$0.058 |
fallen by
42%
|
|
| Future Generation Australia Limited (FGX) ORDINARY FULLY PAID |
Financials |
$562 |
Appendix 4E and Annual Report
|
27 Feb 2026 9:26AM |
$1.420 |
$1.365 |
fallen by
3.87%
|
|
FGX - Price-sensitive ASX Announcement
Full Release
Key Points
- Future Generation Australia's investment portfolio grew by 14.1% in 2025, outperforming the S&P/ASX All Ordinaries Accumulation Index by 3.5%.
- The company's pre-tax net tangible assets (NTA) increased by 12.9% for the year ending 31 December 2025.
- Future Generation Australia paid 7.1 cents per share in fully franked dividends during 2025.
- A social investment of 1.0% was a significant difference between the investment portfolio performance and NTA performance.
- The company has a profits reserve of 43.9 cents per share before the payment of the final dividend.
- Future Generation Australia returned over $298.0 million or 81.6 cents per share in dividends and franking credits since inception.
- The company focuses on supporting vulnerable children aged 0 to 14 years and their caregivers.
- Future Generation Australia has partnerships with 11 not-for-profit organizations for social impact.
- Total allocation to social impact partners in 2025 was $4,063,802.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$134 |
Appendix 4E and Annual Report
|
27 Feb 2026 9:26AM |
$0.875 |
$0.770 |
fallen by
12%
|
|
6KA - Price-sensitive ASX Announcement
Full Release
Key Points
- 6K Additive, Inc issued common stock as part of an IPO, with a significant number of shares allocated to 6K Inc and various nominees.
- The company reported a net loss of over $17 million for the year ended 31 December 2025.
- Revenue primarily came from product sales, with a small contribution from service revenue.
- 6K Additive conducted an IPO and various equity transactions during the year, resulting in changes in the shareholding structure.
- The company incurred significant costs in operating expenses, including selling, general, administrative, and research and development expenses.
- Intangible assets and goodwill were evaluated, with developed technology and customer relationships being major components.
- Equity-based compensation and stock options were part of the employee remuneration strategy.
- There were notable changes in cash flows from operating, investing, and financing activities, with a focus on IPO proceeds and equipment purchases.
- The company maintained a diverse shareholder base, with substantial holdings by 6K Inc and institutions like HSBC Custody Nominees and CITICORP.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pacific Current Group Limited (PAC) ORDINARY FULLY PAID |
Financials |
$325 |
Update - Notification of buy-back - PAC
|
27 Feb 2026 9:25AM |
$10.020 |
$11.650 |
risen by
16.27%
|
|
Call 1300 880 160
Start a chat
Schedule a call
